

CLEANING  
VALIDATION  
PRACTICAL  
COMPLIANCE  
SOLUTIONS FOR  
PHARMACEUTICAL  
MANUFACTURING



Destin A. LeBlanc

[www.pda.org/bookstore](http://www.pda.org/bookstore)

# CONTENTS

---

Foreword	vii
General Topics	1
1. <i>The Applicability of Cleaning Validation</i>	3
2. <i>What's a Contaminant?</i>	7
3. <i>Adequate "Documented Evidence" for Cleaning Validation</i>	11
4. <i>Water Quality for Validated Cleaning Processes</i>	17
Special Situations	23
5. <i>Campaigns and Dedicated Equipment</i>	25
6. <i>Cleaning for Manufacture of Clinical Trial Materials</i>	29
7. <i>What's Really Different about Biotech?</i>	33
8. <i>Cleaning After a Media Fill</i>	39
Residue Limits	43
9. <i>Setting "Dose" Limits without Dosing Information</i>	45
10. <i>What's a Dose for Calculating Limits?</i>	49
11. <i>The Use of Safety Factors in Limits Calculations</i>	53
12. <i>The Use of Default Limits</i>	57
13. <i>Limits for Drugs with Multiple Actives</i>	61

<b>Analytical Methods</b>	<b>65</b>
14. <i>Specificity of Analytical Methods</i>	67
15. <i>More on Specificity of Analytical Methods</i>	73
16. <i>Validation of Analytical Methods</i>	77
17. <i>Why TOC is Acceptable</i>	81
18. <i>TOC Issues: Sampling Methods</i>	85
19. <i>TOC Issues: Appropriate Blanks</i>	89
20. <i>TOC Issues: Blanks for Recovery Studies</i>	93
21. <i>Establishing Adequate Solubility for TOC Analysis</i>	97
22. <i>Correlation of TOC with a Specific Analytical Method?</i>	101
<b>Sampling</b>	<b>103</b>
23. <i>Selecting Swab Sampling Sites</i>	105
24. <i>Sampling the Sampling Rinse</i>	109
25. <i>Correlation of Swab and Rinse Sampling Results</i>	111
26. <i>Is Rinse Sampling Alone Acceptable?</i>	113
27. <i>Using Statistics in Sampling?</i>	119
<b>Sampling Recovery</b>	<b>121</b>
28. <i>Handling Sampling Recovery Results</i>	123
29. <i>Recovery Studies for Rinse Sampling</i>	127
30. <i>Additional Considerations in Recovery Studies: Part 1</i>	131
31. <i>Additional Considerations in Recovery Studies: Part 2</i>	135
32. <i>Using Sampling Recovery Percentages</i>	141
<b>Protocol Issues</b>	<b>143</b>
33. <i>Dirty Equipment Hold Times</i>	145

<i>34. More on DEHT Issues</i>	149
<i>35. Cleaned Equipment Hold Time</i>	151
<i>36. Worst Case Process Conditions</i>	157
<i>37. Defining Three “Consecutive” Runs</i>	161
<b>Grouping Strategies</b>	<b>165</b>
<i>38. Product Grouping Strategies</i>	167
<i>39. Selecting Worst-Case Products for Grouping</i>	173
<i>40. Equipment Grouping Strategies</i>	177
<b>Regulatory Issues</b>	<b>183</b>
<i>41. The New FDA Compliance Program Guidance Manual and Cleaning Validation</i>	185
<i>42. PAT and Cleaning Validation</i>	191
<b>Microbial Issues</b>	<b>195</b>
<i>43. Recovery Studies for Microbial Sampling?</i>	197
<i>44. Endotoxin Issues</i>	201
<b>Visually Clean Issues</b>	<b>205</b>
<i>45. Understanding and Applying “Visually Clean”</i>	207
<i>46. Issues in the Visual Examination of Equipment Surfaces</i>	211
<i>47. Is a Dirty Swab a “Visually Clean” Failure?</i>	215
<b>Validation Maintenance</b>	<b>219</b>
<i>48. Monitoring a Validated Cleaning Process</i>	221
<i>49. Revalidation</i>	225
<b>Index</b>	<b>229</b>